Jul 2026· Integrated Oncology Diagnostics & Treatment· 0 citations
TL;DR
Current evidence on early-onset colorectal cancer epidemiology, biology, clinical presentation, screening, and treatment is summarized, and emerging directions including liquid biopsy, artificial intelligence, and microbiome-based strategies are highlighted.
Abstract
Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before age 50, has
become a rapidly increasing global health concern. In contrast to declining rates in older adults, EOCRC incidence has nearly doubled in several high-income countries since the early 1990s and is rising in more than half of countries worldwide, particularly among individuals born after the 1960s, reflecting a clear birth‑cohort effect. In the United States, colorectal cancer is now the leading cause of cancer-related death in men under 50 and the second leading cause in women of the same age. Although hereditary syndromes such as Lynch syndrome and familial adenomatous polyposis account for 16--20% of cases, most EOCRC is sporadic and linked to environmental exposures, lifestyle factors, gut microbiome dysbiosis, and early‑life influences.
EOCRC displays distinct molecular features compared with late-onset disease, including lower
frequencies of BRAF and KRAS mutations, higher rates of microsatellite instability-high tumors outside hereditary contexts, and enrichment of TP53 and CTNNB1 alterations. Clinically, EOCRC often
presents at advanced stages, shows rectal predominance, and is associated with diagnostic delays of up to six months due to misattribution of symptoms to benign conditions. In response to rising incidence, major U.S. guidelines now recommend initiating colorectal cancer screening at age 45. Treatment increasingly incorporates immunotherapy for mismatch repair-deficient tumors, with neoadjuvant PD‑1 blockade producing exceptional pathological complete response rates. This review summarizes current evidence on EOCRC epidemiology, biology, clinical presentation, screening, and treatment, and highlights emerging directions including liquid biopsy, artificial intelligence, and microbiome-based strategies.
This review critically synthesizes recent evidence on EOCRC epidemiology, risk architecture, life-course carcinogenesis, molecular and microbiome-associated mechanisms, diagnostic delay, screening limitations, treatment considerations, and survivorship needs, with the aim of reframing EOCRC as an age-attuned clinical and biological challenge rather than a simple early presentation of conventional colorectal cancer.
Magda Grześkiewicz-Szostak, K. Gęca, M. Skórzewska· Current Oncology Reports· 0 citations
Background Colorectal cancer (CRC) is increasingly diagnosed in younger adults, with evidence that early-onset cases (age <50 years) differ in the spectrum of prevalent gene mutations compared with older individuals. To evaluate how these age-related differences may inform testing guidelines and therapeutic development, we examined mutation rates of the most prevalent gene mutations across four age-stratified cohorts. Patients and methods Clinicogenomic data were obtained from Memorial Sloan Kettering Center for Harmonized Onco-genomic Research Dataset and China Pan-Cancer cohorts available in cBioPortal. A total of 6762 samples were analyzed. Mutation frequencies for a comprehensive panel of the 100 most prevalent CRC genes were compared across four age groups: 18-29 (n = 79), 30-39 (n = 402), 40-49 (n = 1064), and ≥50 (n = 5217) using chi-square analysis. False discovery rate (FDR) correction for multiple comparisons was carried out using Benjamini–Hochberg procedure. Results Statistically significant variation in mutation frequency across age groups was seen in 22 key genes. APC mutations increased with age and were seen in 49.4% of patients in the 18-29 group, 69.7% in 30-39, 73.3% in 40-49, and 75.25% of patients ≥50 (P < 0.001, FDR < 0.001). The oldest cohort was more than three times more likely to have an APC mutation than the youngest [odds ratio (OR) = 3.74, 95% confidence interval (CI) 2.44-5.74, P < 0.001]. In contrast, SMAD4 mutations were twice as common in the youngest age group at 31.6% compared with those over 40, with a prevalence of 17.29% in patients 40-49, and 18.84% in patients over 50 (OR = 2.03, 95% CI 1.26-3.27, P < 0.001, FDR < 0.001). POLE mutations peaked in the 30-39 age group with a prevalence of 10.7% compared with 6.3% in patients aged 18-29, 4.9% in patients aged 40-49, and 5.9% in patients aged ≥50 (P < 0.001, FDR < 0.001). Individuals in the 30-39 group were nearly twice as likely to carry a POLE mutation compared with those over 40 (OR = 1.96, 95% CI 1.41-2.74, P < 0.001). Conclusions Differences in mutations of key genes including a lower prevalence of APC mutations and increased SMAD4 mutations in younger individuals provides further supporting evidence that early-onset CRC may represent a distinct biological subtype of CRC. Enrichment of POLE mutations in younger patients highlights the importance of expanded molecular profiling in early-onset CRC, which could help identify patients most likely to benefit from immunotherapy and advance personalized treatment strategies in CRC. Together, these findings reinforce the need to approach early-onset CRC as a distinct biological entity and ensure that appropriate molecular assays are incorporated to guide care.
L. Liu, A. Rose, A. Samaddar et al.· ESMO gastrointestinal oncolo...· 0 citations
Critically appraising the existing evidence, this work identifies key knowledge gaps, such as the understudied sporadic EOPC subgroup and the lack of dedicated clinical trials, and proposes future research directions to inform early detection and optimize therapeutic strategies for this unique patient population.
The rising incidence of early-onset colorectal cancer (EOCRC), defined as a diagnosis in adults younger than 50 years, has emerged as a critical global public health challenge. 1 While colorectal cancer (CRC) rates in older populations have stabilized or declined due to successful screening programs, the incidence among younger adults is surging at an unprecedented rate. 2 Projections suggest that by 2030, one-third of all colo-rectal cancers will be diagnosed in individuals under the age of 50. 3 This “unprecedented tumor epidemic” might be driven by a significant birth cohort effect, suggesting that generational shifts in environmental exposures, lifestyle factors, such as obesity, westernized diets, antibiotic usage, and potentially associated alterations in the microbiome are reshaping the epidemiological landscape of CRC. 4 The rising incidence of EOCRC has prompted increasing scientific attention, though substantial knowledge gaps still remain. No specific etiologic factors have been clearly identified, limiting our understanding of disease biology and hindering the development of effective prevention tools and tailored management strategies. Although EOCRC shows distinct clinical and pathological features, clear associations with specific molecular alterations have not yet been demonstrated. As a result, no obvious molecular targets have emerged so far to support the development of dedicated targeted therapies. Moreover, EOCRC affects individuals during the most productive years of life, adding complexity to their clinical management. Patients face a broad range of unmet needs including fertility, relationships, career, and long-term survivorship, which are often insufficiently addressed within current care models. The higher prevalence of hereditary cancer
A. Puccini, C. Cremolini· The Lancet Regional Health -...· 0 citations
Traditional environmental risk factors and established common genetic variants are not associated with the rising incidence of early-onset colorectal cancer, and drivers of early-onset disease might include novel environmental exposures or early-life factors beyond traditional risk assessment.
Anmol Nigam, Chidiebere Onongaya, Pravin Meshram et al.· Diseases of the Colon & Rect...· 0 citations
Simple Summary Colorectal cancer diagnosed before age 50 is becoming more common in many countries, although the reasons remain uncertain. This review examined 75 publications on lifestyle, metabolic, clinical, medication-related, and social factors associated with early-onset disease. The clearest associations involved excess body weight and poor metabolic health. Physical inactivity, smoking, alcohol consumption, and dietary patterns showed less consistent associations, while inflammatory bowel disease emerged as a clinical risk condition. Evidence on medications and social conditions was limited. Many of these factors influence colorectal cancer at older ages; their relevance to earlier-onset disease may depend on when exposure begins, its duration, and how exposures interact over time. The findings support prevention throughout the life course with healthier food and activity environments, tobacco control, reduced harmful alcohol use, and better metabolic health. However, observational evidence does not establish that any single factor causes early-onset colorectal cancer or should independently determine screening eligibility.
A. Alegre-Martínez, L. Cabañas-Alite, I. Fernández-Benet et al.· Cancers· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
